Cytheris SA, a clinical stage biopharmaceutical company focused on
research and development of new therapies for immune modulation, today
announced that it has received a Notice of Allowance from the U.S.
Patent and Trademark Office (USPTO) for its patent application
"Glycosylated IL-7, Preparation and Uses", US Patent Application Number
11/996,176. The Notice of Allowance is the USPTO’s official
communication that the Company’s application has successfully completed
examination and that a patent will be issued.
“This
patent, together with our recently issued patent covering IL-7
pharmaceutical composition, provides broad protection for Cytheris’
recombinant human interleukin-7 (CYT107), a critical immune-modulator
for immune T-cell recovery and enhancement, and extends this protection
in the U.S. to 2026.”
"We are pleased to announce receipt of this Notice of Allowance by the
USPTO," said Michel Morre, DVM, President and CEO of Cytheris. “This
patent, together with our recently issued patent covering IL-7
pharmaceutical composition, provides broad protection for Cytheris’
recombinant human interleukin-7 (CYT107), a critical immune-modulator
for immune T-cell recovery and enhancement, and extends this protection
in the U.S. to 2026.”
Together these two patents protect an IL-7 composition for therapeutic
use containing the purified protein as a drug substance with the correct
disulfide bridging, the appropriate glycosylation profile and
polypeptidic purity. This latest patent also protects various
hyperglycosylated analogs and various fusion proteins.